Prosecution Insights
Prosecution Insights
Tech Center 3900 • Art Units: 1618 3991
This examiner grants 68% of resolved cases
Dameron Levest Jones is an examiner in Tech Center 3900 and Art Unit 1618. The profile shows 1085 resolved cases and an allowance rate of 67.7 percent. The total number of resolved cases establishes the reliability of the prosecution data. This specific percentage of 67.7 helps practitioners estimate the likelihood of an application reaching an allowance.
The interview lift is 31.3 percent. This figure shows the difference in allowance probability when an interview is conducted. Practitioners can use the 31.3 percent lift to evaluate the utility of direct communication with the examiner during prosecution. This metric serves as a guide for deciding whether to request a formal discussion.
The median days to allowance is 1269. This period represents the middle value of the time taken to reach an allowance. With 1085 resolved cases, the 1269-day duration characterizes the experience for applications assigned to this examiner. Practitioners should plan for this timeline when seeking a grant in Art Unit 1618.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19443984 | CHEWABLE COMPOSITIONS | Final Rejection | Harmony Foods LLC |
| 18716761 | CLOSO-DODECAIODODECABORATE COMPLEXES AND METHODS OF USE FOR SAME | Non-Final OA | The Regents of the University of California |
| 17630286 | CELL PENETRATING PEPTIDE FUNCTIONALIZED PERFLUOROCARBON NANOEMULSION COMPOSITIONS AND METHODS FOR IMAGING CELL POPULATIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18039301 | ROOM-TEMPERATURE PHOSPHORESCENCE NANOPARTICLES AND METHODS OF MAKING THE SAME | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18329245 | CASPASE-3-TRIGGERED MOLECULAR SELF-ASSEMBLING PET PROBES AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17628497 | PARTICLE-BASED METHOD FOR DEFINING A GUT MICROBIOTA IN HUMANS OR OTHER ANIMAL SPECIES | Non-Final OA | Washington University |
| 17844456 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | Non-Final OA | California Institute of Technology |
| 17873980 | IN SITU FORMING COMPOSITE MATERIAL FOR TISSUE RESTORATION | Non-Final OA | The Johns Hopkins University |
| 18041470 | TEXAPHYRIN DERIVATIVES FOR MANGANESE CHEMOTHERAPY, PHOTOACOUSTIC IMAGING, AND PHOTOTHERMAL THERAPY | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17905124 | METHODS AND COMPOSITIONS FOR TREATMENT OF APC-DEFICIENT CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 17782147 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 17730130 | REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES | Final Rejection | University of Washington |
| 18573604 | Compounds For Molecular Imaging of Collagen Turnover and Methods Using Same | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18515076 | DIMERIZATION STRATEGIES AND COMPOUNDS FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY | Non-Final OA | University of Pittsburgh - of the Commonwealth System of Higher Education |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | Non-Final OA | PRELUDE CORPORATION |
| 17741686 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | Final Rejection | University of Louisville Research Foundation, Inc. |
| 18711699 | HAFNIUM (IV) OXIDE NANOPARTICLES AND AQUEOUS COMPOSITIONS THEREOF | Non-Final OA | UNIVERSITEIT GENT |
| 18815955 | Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle | Non-Final OA | Translate Bio, Inc. |
| 18689166 | ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR | Non-Final OA | Beijing Inno Medicine Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy